Fabry disease and vascular risk factors: Future strategies for patient-based studies and the knockout murine model

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue SUPPL. 451, 2006, Pages 69-71

  Moore, David F ^a   Gelderman, Monique P ^b   Fuhrmann, Steven R ^c   Schiffmann, Raphael ^d   Brady, Roscoe O ^d   Goldin, Ehud ^d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Laboratory of Cellular Hematology   (United States)

^c IOMAI Corporation   (United States)

^d Developmental and Metabolic Neurology Branch   (United States)

Author keywords

Fabry disease; Gene expression

Indexed keywords

ALPHA GALACTOSIDASE; DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME DEFICIENCY; FABRY DISEASE; GENE EXPRESSION; KNOCKOUT MOUSE; LYSOSOME STORAGE DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; DISEASE MODELS, ANIMAL; FABRY DISEASE; HUMANS; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 33646684298     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035320600618932     Document Type: Conference Paper

References (19)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967;276:1163-7.
2. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease, 8th edn. New York: McGraw-Hill; 2001. p. 3733-74.
3. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996;40:8-17.
4. Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. Am J Neuroradiol 2003;24:1096-101.
5. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001;32:1559-62.
6. Moore DF, Altarescu G, Pursley R, Campia U, Panza JA, Dimitriadis E, et al. Arterial wall properties and Womersley flow in Fabry disease. BMC Cardiovasc Disord 2002;2:1.
7. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001;104:1506-12.
8. Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-31.
9. Moore DF, Herscovitch P, Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 2001;11:303-7.
10. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Abnormal cerebrovascular reactivity in Fabry disease is reversed following enzyme replacement therapy. BMC Neurology 2002;2:4.
11. Moore DF, Ye F, Brennan ML, Gupta S, Barshop BA, Steiner RD, et al. Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging 2004;20:674-83.
12. Schiffmann R, Kopp JB, Austin HA, 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
13. Bodary PF, Shen Y, Vargas FB, Bi X, Ostenso KA, Gu S, et al. Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 2005;111:629-32.
14. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, et al. α-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 1997;94:2540-4.
15. Ohshima T, Schiffmann R, Murray GJ, Kopp J, Quirk JM, Stahl S, et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 1999;96:6423-7.
16. Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, et al. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. J Neurochem 2001;79:1217-24.
17. Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiffmann R. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003;62:231-40.
18. Moore DF, Li H, Jeffries N, Wright V, Cooper RA, Jr, Elkahloun A, et al. Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation 2005;111:212-21.
19. http://cran.r-project.org.